US trial starts for stentless tissue valve:
This article was originally published in Clinica
Executive Summary
St Jude Medical has performed the first US implant of its next-generation stentless tissue valve, as part of an FDA approved trial. The Toronto Root bioprosthesis combines the firm's Toronto SPV valve with its BiLinx anticalfication technology, which St Jude claims is the only technology designed to reduce calcification on the aortic wall as well as on the aortic leaflets. The St Paul, Minnesota company recently began a limited market launch of the product in Europe.